Form 8-K - Current report:
SEC Accession No. 0001193125-22-146467
Filing Date
2022-05-10
Accepted
2022-05-10 17:24:00
Documents
13
Period of Report
2022-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d275369d8k.htm   iXBRL 8-K 24492
2 EX-99.1 d275369dex991.htm EX-99.1 84154
  Complete submission text file 0001193125-22-146467.txt   242439

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20220505.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20220505_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20220505_pre.xml EX-101.PRE 10809
7 EXTRACTED XBRL INSTANCE DOCUMENT d275369d8k_htm.xml XML 3199
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 22911140
SIC: 2834 Pharmaceutical Preparations